Treatment of acute leukemia with 5-azacytidine (NSC-102816).
about
Safety and efficacy of azacitidine in myelodysplastic syndromesEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineSPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.Epigenetic therapies in MDS and AMLAzacitidine in the management of patients with myelodysplastic syndromes.
P2860
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
description
1973 nî lūn-bûn
@nan
1973 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1973 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1973年の論文
@ja
1973年学术文章
@wuu
1973年学术文章
@zh-cn
1973年学术文章
@zh-hans
1973年学术文章
@zh-my
1973年学术文章
@zh-sg
1973年學術文章
@yue
name
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
@ast
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
@en
type
label
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
@ast
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
@en
prefLabel
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
@ast
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
@en
P2093
P1476
Treatment of acute leukemia with 5-azacytidine (NSC-102816).
@en
P2093
E J Freireich
J U Gutterman
K B McCredie
M A Burgess
M P Sullivan
V Rodriguez
P304
P577
1973-09-01T00:00:00Z